1. Home
  2. |Insights
  3. |FTC Intervenes in the Formation of Proposed Joint Venture Between Boeing and Lockheed Martin

FTC Intervenes in the Formation of Proposed Joint Venture Between Boeing and Lockheed Martin

Client Alert | 1 min read | 10.09.06

On October 3, 2006, the FTC filed a complaint intervening in the formation of a joint venture between The Boeing Company and Lockheed Martin Corp. Announced in May of 2005, the joint venture, United Launch Alliance, is designed to consolidate manufacturing and development of the companies' expendable launch vehicles. The FTC's complaint argues that the joint venture would violate Section 7 of the Clayton Act and Section 5 of the FTC Act, as amended. Boeing and Lockheed are the only two companies that supply medium to heavy launch services to the U.S. government, so competition in that market would be reduced. The FTC unanimously approved a consent order requiring the venture to cooperate with all providers of government space vehicles, provide equal consideration and support to all launch service providers when seeking any U.S. government delivery in orbit contract and to safeguard competitively sensitive information obtained from other space vehicle and launch services providers.

Click for more information on the FTC intervention in the proposed joint venture between Boeing and Lockheed Martin.

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...